AstraZenecaAssociate Director, Global Oncology Commercial Strategy (GI Cancers)
Aug. 2023Washington DC-Baltimore AreaLead market research, forecasting, and advanced analytics for U.S., EU5, China, & Japan in early hepatocellular carcinoma (HCC), resectable/early and advanced biliary tract cancers (BTCs), locally advanced / unresectable esophageal squamous cell carcinoma (ESCC), and resectable gastric and gastroesophageal junction cancer (GC/GEJC) Executed global launch in early HCC, collaborating closely with Global Commercial colleagues to understand the disease area, market opportunity, HCP archetypes in a complex indication (e.g., High Risk of Recurrence eHCC is not defined in guidelines) Responsible for insights and market assessment for cross-functional deliverables across multiple assets (e.g., I-O, ADCs, bi-specifics), including Tumor Strategy Plans for BTC, HCC, & Gastric Cancers Responsible for insights and market assessment for brand deliverables in aBTCs, eHCC, GEJC/GC, and locally advanced ESCC